Shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Get Free Report) fell 1.1% on Tuesday . The company traded as low as $3.42 and last traded at $3.45. 12,917 shares were traded during mid-day trading, a decline of 83% from the average session volume of 75,676 shares. The stock had previously closed at $3.49.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Kiora Pharmaceuticals in a report on Thursday, August 22nd.
View Our Latest Analysis on Kiora Pharmaceuticals
Kiora Pharmaceuticals Stock Down 1.1 %
Kiora Pharmaceuticals (NASDAQ:KPRX – Get Free Report) last issued its earnings results on Friday, August 9th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.95) by $0.42. The firm had revenue of $0.02 million during the quarter. Equities analysts predict that Kiora Pharmaceuticals, Inc. will post 1.17 EPS for the current fiscal year.
Institutional Investors Weigh In On Kiora Pharmaceuticals
A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC acquired a new stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals comprises approximately 0.8% of Stonepine Capital Management LLC’s holdings, making the stock its 16th biggest position. Stonepine Capital Management LLC owned 6.86% of Kiora Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 76.97% of the company’s stock.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.
Featured Articles
- Five stocks we like better than Kiora Pharmaceuticals
- What Do S&P 500 Stocks Tell Investors About the Market?
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Stock Average Calculator
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Following Congress Stock Trades
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.